About
Rare Genetic Diseases
Areas of Focus
Categories
Small Molecule PharmaceuticalMiddle East
Team (2)
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
191
By Phase
PHASE2: 4PHASE1: 4
By Status
COMPLETED: 5TERMINATED: 2UNKNOWN: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT05448755Lead Sponsor
A Study of ELX-02 in Patients With Alport Syndrome
PHASE2Unknown
8 participants
Started: Nov 28, 2022 · Completed: May 30, 2023
NCT04135495Lead Sponsor
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
PHASE2Completed
17 participants
Started: Nov 25, 2019 · Completed: Oct 3, 2022
NCT04126473Lead Sponsor
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
PHASE2Completed
17 participants
Started: Nov 5, 2019 · Completed: Apr 6, 2022
NCT04069260Lead Sponsor
A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
PHASE2Terminated
3 participants
Started: Aug 2, 2019 · Completed: Dec 17, 2019
NCT03776539Lead Sponsor
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
PHASE1Completed
24 participants
Started: Jan 4, 2019 · Completed: Aug 7, 2019
Locations (1)
Headquarters
Nes Tziona, Israel
Map
Loading map...